Cross-reactive human antibody responses to H9N2 influenza virus, New York, United States, 2025
Assessed cross-reactive antibody responses to H9N2 viruses using a panel of recently collected human sera from the general population of a large metropolitan city in North America (New York City).
Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults
Pre-existing immunity to subclade K variants was noted with seasonal influenza vaccination further boosting titres two-fold against subclade K and three-fold against the vaccine-like strain...
Cross-reactive human antibody responses to H5N1 influenza virus neuraminidase are shaped by immune history
Early access - Individuals likely primed in childhood with H1N1 viruses possessed higher levels of antibodies that cross-react with the NA of H5N1 viruses compared to those primed with H2N2 or H3N2 viruses.
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections
AAN-I-IFNs+ patients with life-threatening COVID-19 pneumonia harbor circulating type-I IFN-specific B cells indistinguishable from patients bearing T cell tolerance defects of genetic origin.
Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity
These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.
Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies
Findings indicate that population-level immunity to clade 2.3.4.4b H5 viruses is dominated by NA-directed antibodies, with important implications for pandemic risk assessment.
MF59-adjuvanted A/Astrakhan influenza vaccine induces cross-neutralizing H5N1 antibodies in ferrets against circulating clade 2.3.4.4b viruses
Findings suggest broad protection induced by the CSL Seqirus pandemic vaccine against contemporary clade 2.3.4.4b A(H5N1) viruses.
Small molecule–constrained paratope mimetic bicyclic peptides as potent inhibitors of group 1 and 2 influenza A virus hemagglutinins
Authors report on the applicability of a CLIPS (chemical linkage of peptides onto scaffolds) chemistry–based strategy to miniaturize an anti-influenza hemagglutinin (HA) antibody into design of stable and functional bicyclic peptides.
